CPHI Podcast Series: The Supplements Market – From Slump to Surge
The latest instalment in the CPHI Podcast Series dives into the world of supplements and explores the impact of COVID-19 on this booming market
The supplements market is on the rise, with products like vitamins, herbal drinks, and protein powders found in more household cupboards than ever before. The increasing popularity of supplements has coincided with the rise of wellness culture and increasing interest in preventative healthcare, spurred by the COVID-19 pandemic. In fact, the market was starting to decline before emergence of the coronavirus reignited global sales.
Supplements can be an excellent way to cover deficiencies not addressed by food intake, but the wide range of products available in health food shops, pharmacies and supermarkets can be overwhelming for consumers. And while market growth is expected to continue, products such as herbal supplements and CBD continue to face regulatory issues and scrutiny over the soundness of their health claims.
To discuss the latest trends in the supplements space, we’re joined this month by David Ridley, Senior Editor at HBW Insight and host of Over the Counter podcast. He tells us which products surged in popularity during the pandemic, discusses the rise of self-care, and gives an overview of the regulatory environment in Europe.
Related News
-
News How to disrupt an industry as big as pharma for the better?
In this interview, hear from Matthew Wise, Head of Data at CCD Partners, on the companies they've been looking into that are offering new and interesting perspectives that have the potential to shake up the pharmaceutical industry, and how they'... -
News CPHI Pharma Awards 2024: Meet the winners from the CPHI Celebration
This year we had a lot to celebrate, the 35th Anniversary of CPHI, and our esteemed award winners, of which we included two additional categories this year, the Future Leader award, and Woman of the Year award. -
News CPHI Milan 2024 - From the Floor
Milan and CPHI welcome you to 2024 CPHI Milan! As we celebrate the 35th edition of our flagship CPHI show, editors Vivian Xie and Lucy Chard bring you the latest from the show floor, conference sessions, and innovative solutions from all exhibitors, at... -
.png)
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News A Day in the Life of a Global CDMO Chapter Lead – Manufacturing
The 'Day in the Life of' series has covered many aspects of the pharmaceutical pipeline, including R&D and procurement, now we're taking a look at manufacturing from a global CDMO perspective. -
.png)
News Eisai Alzheimer’s drug authorised in UK but still faces obstacles
In partnership with BioArctic AB, pharmaceutical company Eisai has been granted Marketing Authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) for its Alzheimer’s disease drug product Leqembi. -
.png)
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance